Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Preliminary JAMA analysis finds no link between COVID-19 vaccines and sudden hearing loss

By Brian Buntz | May 21, 2021

COVID-19 therapies vaccines coronavirus

[Photo by Daniel Schludi on Unsplash]

After the authorization of COVID-19 vaccines, a growing number of sudden sensorineural hearing loss (SSNHL) reports have emerged from recently vaccinated people. 

A recently published analysis in JAMA is among the first to consider whether COVID-19 vaccines play a role in SSNHL, which frequently occurs without a clear underlying cause.  

Drawing from a pool of SSNHL patients who presented at Johns Hopkins University and data from the Vaccine Adverse Events Reporting System (VAERS) database, the researchers compared the observed number of SSNHL with the expected rate in the broader population. In the latter, there were 147 SSNHL reports between December 14, 2020, and March 2, 2021, that occurred within three weeks of vaccination and had high credibility of reporting. In that time frame, 86,553,330 doses of COVID-19 were administered in the U.S. 

[Related: No clear link between COVID-19 vaccines and sudden hearing loss]

The researchers concluded that the SSNHL rates among the vaccinated cohort are consistent with — and possibly less than — the background rate in the general population. While noting that the findings are preliminary, the study authors conclude that “no association exists between inoculation with a SARS-CoV-2 messenger RNA vaccine and incident sudden hearing loss.” 


Filed Under: Infectious Disease
Tagged With: COVID-19 vaccines, mRNA vaccines, SARS-CoV-2 messenger RNA vaccine, SSNHL, sudden sensorineural hearing loss
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech
FDA allows booster dose Pfizer-BioNTech COVID-19 vaccine in children 5 to 11
AstraZeneca RQ Biotechnology
AstraZeneca paying up to $157M for broad-spectrum monoclonal antibodies against COVID
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative
Olumiant
FDA approves Olumiant for treating some hospitalized COVID-19 patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50